ISSN (Print): 1389-2002
ISSN (Online): 1875-5453
Volume 19, 14 Issues, 2018
Download PDF Flyer
Open Access Funding
ISSN (Print): 1389-2002
ISSN (Online): 1875-5453
Aims & Scope
Science Citation Index-Expanded (SciSearch)TM, Journal Citation Reports/Science Edition, Index to Scientific Reviews®, Biochemistry & Biophysics Citation IndexTM, Current Contents® - Life Sciences, BIOSIS, BIOSIS Previews, BIOSIS Reviews Reports and Meetings, MEDLINE/PubMed/Index Medicus, Scopus, EMBASE/Excerpta Medica, Chemical Abstracts Service/SciFinder, ProQuest, ChemWeb, Google Scholar, PubsHub, MediaFinder®-Standard Periodical Directory, Genamics JournalSeek, J-Gate, CNKI Scholar, Suweco CZ, TOC Premier, EBSCO, British Library and Ulrich's Periodicals Directory.
Ranking and Category:
Submit Abstracts / Manuscripts Online
Michael Sinz Bristol Myers Squibb Wallingford, CT USA
View Full Editorial Board
5 - Year: 2.972
Order Your Article Before Print
Self Archiving Policies
Instructions for Authors
Free Copies Online
Open Access Articles
Most Cited Articles
Advertise With Us
Most Accessed Articles
Most Popular Articles
Special Issue Submission
"Current Drug Metabolism is an important new source of current and comprehensive reviews that are of interest to drug metabolism scientists working in academia, industry and government."
David S. Riddick
Univ. of Toronto, Canada
We would like to express our gratitude to Bentham Science Publishers for the wonderful experience while working with the journal on this mini-thematic issue. There are several reasons for this enthusiasm.
We are grateful to the Editor-in-Chief, for contacting us and offering us the chance to publish in Current Drug Metabolism, and accepting our proposal for a mini-thematic issue.
It was a wonderful experience working with the members of the Editorial Office at the time of the submission and processing of the papers. They were always ready to support us whenever we had either a problem or a query.
We would like to acknowledge the high standard of all others who took care of the editing and processing the papers to obtain the best final quality at the time of publication.
(Genitourinary Cancer Program Institute of Pathological Anatomy and Histopathology Polytechnic University of the Marche Region (Ancona) School of Medicine United Hospitals Via Conca, 71 60126 Torrette, Ancona, Italy)
Has contributed: Mirna Expression In Bladder Cancer And Their Potential Role In Clinical Practice.
52 Articles Ahead of Print are available electronically
Mental disorders such schizophrenia, depression, bipolar and anxiety disorders are leading causes of disability and multimorbidity in the
modern society. In recent years, major advances were made in order to understand the molecular basis of these disorders aiming to discover
potential new drugs. Unfortunately, the majority of these efforts have been unsuccessful. Many other studies have been focused on understanding
the mechanism of action of drugs used for the treatment of neuropsychiatric disorders, such as antidepressants, mood stabilizers and
antipsychotics using isolated systems. Many incredible discoveries were made which allowed us to develop better treatment options to improve
the quality of life of patients struggling with these disorders.
Today, clinicians and scientists are combining forces to better understand different connections of the brain-body relationship that were
refuted for many years because of the general idea of the brain as an independent and isolated tissue. The concept of a two-way relationship
between depression and cardiovascular disease, or the gut-brain axis is only gaining more space and credibility. We are in the moment of
understanding how our complex body is interconnected in the way that a single insult in a remote part of our body could lead to molecular
changes in our brain.
We are also better understanding the side effects of distinct drugs, such as antidepressants, and their impact on a population with cardiovascular
disease or the relationship between long-term lithium intake and cancer proliferation. More studies are still needed to confirm these
suggestions; however, they are thought-provoking.
This thematic issue, devoted to the study of current pharmacological treatments involved in mental disorders introduce an interesting interface
intended to explore (i) the safety limits of the use of antidepressants on cardiovascular function , (ii) the cross-talk between inflammation
in depression and cardiovascular disease , (iii) the involvement of microbiota in the etiopathogenesis of mental illness , (iv)
the relationship between lithium intake and cancer proliferation  and (v) the applicability of targeting GSK-3B for several incurable neuropsychiatric
It is evident that science reached a time where scientists and clinicians are combining strengths to better comprehend the molecular basis
of pharmacological treatments to study the diseases as they occur; in combination, and not isolated. In this new era of technology and information,
combining forces in a multidisciplinary environment to understand the pathological basis will only improve the treatment options and
the quality of life of patients with psychiatric disorders.
Chronic kidney disease (CKD) leading to kidney failure is becoming a global public health
problem. Acute kidney injury (AKI) is also a major kidney disease characterized by a rapid
decline of renal function. Drug-induced nephrotoxicity is a contributing factor to AKI in
19-25% of critically ill patients. Drugs exert their toxic effects to cause nephrotoxicity by one
or more common pathogenic mechanisms. The progressive loss of kidney function associated
with CKD not only leads to impaired renal excretion of numerous drugs and their metabolites
in the kidneys, but also alters the non-renal disposition of moieties that are extensively
metabolized by the liver. Various alterations in activity of metabolic enzyme system have
been reported in CKD models, for example, reductions in expression and activity of hepatic
cytochrome P450 (CYP) enzymes including CYP3A1, CYP3A2, CYP2C11, and other
enzymes such as N-acetyltransferases. What’s more, other mechanisms such as the
dysregulation of drug transporter systems are involved in decreasing the clearance of drugs in
renal failure. With the development of renal failure, the renal secretion of organic ions
mediated by organic anion transporters (OATs) and organic cation transporters (OCTs) is
decreased. Some organic anionic uremic toxins may directly inhibit the renal excretion of
various drugs and endogenous organic acids by competitively inhibiting OATs.
The objective of this mini-thematic issue is to report recent studies about most common
mechanisms of drug-induced nephrotoxicity and prevention strategies, the alterations of drug
enzymes and transporters in the kidney and liver in renal failure, the potential model systems
to predict drug efficacy, interactions, and drug-induced kidney injury in drug development.
Neurological disorders cover a wide range of diseases; suffering patients all around the world. A study in UK shows about six percent of
the population involved with neurological disorders . Also, investigations stated that the imposed cost of these disorders is an important
challenge for European societies . Therefore, there are too many investigations to find new medical approaches and remedies to treat or
manage neurological disorders. Natural products as well as complementary and alternative therapies are as the sources to find such therapeutics
that are going to be more popular in the society. There are too many traditional and complementary systems of medicine, mostly with
historical roots in ancient eras like Chinese medicine, Persian medicine, Ayurveda, Homeopathy, etc.  Alongside raising the popularity of
using natural and traditional medications, interest of researchers to evaluate their efficacy and safety is going to be raise up. On the other
hand, this popularity causes some concerns including the safety and probable interactions between these remedies with common drugs. Therefore,
investigations to find the efficacy and safety of them with the help of accepted and academic methods are too important.
World Health Organization (WHO) approves and encourages traditional therapies integrated with current and conventional medicine. It
means using the opportunities in both medical systems, traditional and conventional medicines . It is important to integrate Traditional and
Complementary Medicine (T&CM) approaches to current medical systems. It is not only necessary for using T&CM opportunities to manage
and treat neurological disorders and decrease the costs of treatment, but to find any probable side effects and interactions with such remedies.
Therefore, in the first step, it needs scientific investigations to find T&CM drugs’ efficacy, safety and toxicology and then, in the next step
training the neurologists and pharmacists is too important.
Therefore, this thematic issue of Current Drug Metabolism aims to publish some valuable reviews on the principles, suggestions, efficacy
of drugs and also herb-drug interactions of some types of T&CM systems in some neurological disorders; providing scientific data and discussions
for medical practitioners, pharmacists and researchers in this field.
This thematic issue will provide a platform to share comprehensive information on advances and recent trends
in various prophylactic and therapeutic regimens to effectively combat various diseases and other health
problems, both infectious and non-infectious posing challenge to the humans and their companion animals
(livestock & poultry). It will focus mainly on the novel, emerging and valuable alternate / complementary
frontier therapeutic options especially in the era of emerging and rising drug resistance in microbial pathogens
and increasing health disorders and conditions of high concerns due to changing life style and other various
predisposing factors. Advances and interdisciplinary approaches of biotechnology, molecular biology,
genetics, cellular immunology, immunomics, proteomics, pharmacology, bioinformatics, nanotechnology and
others for designing and developing newer and effective therapeutic modules would be given priority. These
will include phages, enzybiotics, apoptins, cytokines, monoclonal antibodies, egg yolk antibodies, TLR, stem
cells, si-RNA, nanomedicines, nutritional immunomodulation, probiotics, antioxidants, phytonutrients, and
herbal medicines, which could play promising role in curbing evolving pathogenic threats by their potent
antimicrobial potential, treating non-infectious diseases, metabolic disorders, cancers as well as various
general health problems. Other potential candidates being explored for targeting development of valuable
medicines, drugs, pharmaceuticals, immunotherapeutics, antitoxins, tissue growth factors, gene therapy,
regenerative medicines, therapeutic biologics, modern vaccines and vaccines based therapies will also be
considered. Trends and advances in pharmacogenomics aided drug development and therapeutics,
pharmacokinetics, pharmacodynamics and metabolism of effective/newer drugs and medicines, upcoming
drug designing and novel drug delivery methods will also be given due attention. The compilation will be
useful for medical and veterinary professionals, clinicians, researchers, students/scholars, public health
experts, animal producers, and pharmaceutical industry in designing and adapting effective and safer
therapeutics from clinics to the laboratory for countering important diseases. This thematic issue will accept
submissions of comprehensive review papers on above mentioned topics / theme with their basics, modes of
action, medicinal values, beneficial health applications, modern trends and advances, perspectives, which
could lead to designing and development of effective therapeutics, drugs/medicines, nutraceuticals and
pharmaceuticals in the area of biomedicine with an aim to safeguard health of both humans and animals in a
Recent developments in nanomaterials for the therapy of deadliest diseases have gained significant interest because of their
advantages, such as reduction in systemic toxicity, easy surface functionalization with passivation and targeting moieties, and
enhanced drug accumulation in specific tissue. Nanomedicines and nanomaterials can be administrated by different strategies,
including oral, local, intravenous, and transarterial administration, which are the underlying determinants for their therapeutic
efficacy, pharmacokinetics and pharmacodynamics. In order to optimize the therapeutic outcomes, careful design and synthesis
of nanomedicines are guided by the administration strategies. It requires a broad-system view for innovative nanomaterials and
their clinical applications. The aim and scope of the issue is to introduce Current Drug Metabolism readers to this important
topic of efficacy, toxicology, and PK/PD of nanomedicine administrated by different strategies.
I would like to thank Editor-in-Chief, Michael Sinz, for his support and all authors for their contribution to this special
issue. I am grateful for all peer reviewers’ time and expertise, which help to improve quality of articles. I also thank Maryam
Shaikh for the excellent coordination in publication process.
No Text Found